STOCKHOLM , March 17, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the US FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation (ODD) to exidavnemab for the treatment of Multiple System Atrophy (MSA), providing incentives for the development of treatments for rare diseases with a high medical need. Multiple System Atrophy (MSA) is a rapidly progressive and fatal rare disease affecting the central and autonomic nervous systems.

PITTSBURGH , March 13, 2025 /PRNewswire/ --  MSA Safety Incorporated (NYSE: MSA) today announced it has accepted the resignation of its Chief Financial Officer, Lee B. McChesney, effective March 21, 2025.

MSA Safety Incorporated (NYSE:MSA ) Q4 2024 Earnings Conference Call February 13, 2025 10:00 AM ET Company Participants Larry De Maria - Executive Director of IR Steven Blanco - President and CEO Lee McChesney - SVP and CFO Conference Call Participants Ross Sparenblek - William Blair Saree Boroditsky - Jefferies Jeff Van Sinderen - B. Riley FBR Operator Good day, and welcome to the MSA Safety Fourth Quarter and Full Year 2024 Earnings Conference Call.

MSA Safety (MSA) came out with quarterly earnings of $2.25 per share, beating the Zacks Consensus Estimate of $2.22 per share. This compares to earnings of $2.06 per share a year ago.

Fourth Quarter 2024 Highlights Achieved net sales of $500 million, a 1% GAAP increase and 2% organic(a) increase year-over-year Generated GAAP operating income of $118 million, or 23.5% of sales, and adjusted operating income of $120 million, or 24.0% of sales Recorded GAAP net income of $88 million, or $2.22 per diluted share, and adjusted earnings of $89 million, or $2.25 per diluted share Invested $14 million for capital expenditures, repaid $43 million of debt, returned $20 million to shareholders through dividends and repurchased $10 million of common stock Full Year 2024 Highlights Achieved net sales of $1.8 billion, a 1% GAAP increase and 2% organic increase year-over-year Generated GAAP operating income of $389 million, or 21.5% of sales, and adjusted operating income of $414 million, or 22.9% of sales Recorded GAAP earnings of $285 million, or $7.21 per diluted share, and adjusted earnings of $305 million, or $7.70 per diluted share Invested $54 million for capital expenditures, repaid $94 million of debt, returned $79 million to shareholders through dividends and repurchased $30 million of common stock Improved strong financial position with net leverage of 0.7x and ample liquidity PITTSBURGH , Feb. 12, 2025 /PRNewswire/ -- Global safety equipment and solutions provider MSA Safety Incorporated (NYSE: MSA) today reported financial results for the fourth quarter and year ended December 31, 2024. (a)  Definition of organic revenue growth provided on the bottom of page eight.

MSA to Feature FieldServer Gateways Designed to Enhance Network Protocol Connectivity  PITTSBURGH , Feb. 6, 2025 /PRNewswire/ -- The spotlight on refrigerant leak detection, monitoring and reporting has never been brighter as the HVAC and refrigeration (HVAC-R) industry navigates regulatory changes in their market. To help HVAC-R businesses address these changes, MSA Safety, Inc. (NYSE: MSA) will be showcasing its leak detection and monitoring management solution capabilities at next week's AHR Expo in Orlando, Florida, February 10th through 12th.

PITTSBURGH , Feb. 3, 2025 /PRNewswire/ -- MSA Safety Incorporated (NYSE: MSA), a global leader in the development of advanced safety products and solutions that protect people and facility infrastructures, today announced that it will host the company's fourth quarter and full year 2024 earnings conference call on Thursday, February 13, 2025, at 10:00 a.m. Eastern Time.

Highlights Topline data for ATH434-201 randomized, double-blind Phase 2 clinical trial on track for expected release by early February 2025 ATH434-201 trial in early-stage MSA completed in November 2024 Positive interim data presented at MDS from the ATH434-202 Phase 2 trial in advanced MSA Multiple data presentations and publications showing the potential for ATH434 to modify disease progression in neurodegenerative conditions Cash balance on 31 December 2024 of A$4.54 m MELBOURNE, Australia and SAN FRANCISCO, Jan. 24, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today released its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 31 December 2024 (Q2 FY25). “The second fiscal quarter of this year was extremely productive for Alterity and highlighted the tremendous potential of our lead asset, ATH434, as a promising therapy to treat a variety of neurodegenerative diseases,” said, David Stamler, M.D.

Today's Dividends Kings are a who's-who of the most successful dividend growth stocks of our time. This list consists of about 50 publicly traded companies that have increased their dividend payments annually for a minimum of half a century.

Seven Dividend Aristocrats are trading at 52-week lows, but if they return to their historical fair value, they could offer a 34% upside potential in 2025. These aristocrats have strong fundamentals, including a 2.1% yield, A-credit ratings, and an average 41-year dividend growth streak. Historically, these stocks have outperformed the S&P 500 with lower volatility, delivering consistent returns and robust income growth.